Ulthera Receives $22.5 Million in Series B Round

Ulthera, Inc., a therapeutic ultrasound medical device company
serving the aesthetics market, today announced that it has received
$22.5 million in a Series B round that was led by New Enterprise
Associates (NEA). Existing investor 3i also participated in the round.

"There is a large, rapidly-growing market for cosmetic procedures,
and Ulthera´s technology appears to have several distinct advantages
over existing energy-based offerings, including greater predictability
of results and shorter procedure times," said Chip Linehan, NEA
General Partner, who will join the Ulthera Board of Directors. "NEA is
excited to partner with Ulthera´s founders and its strong, experienced
management team as the company advances its pipeline of potential
products utilizing this innovative technology platform."

"As Ulthera executes our global product development and
commercialization strategy, we welcome the expertise NEA brings to the
company and are very pleased to have Chip join our Board," said Matt
Likens, President and CEO of Ulthera. "Clearly the company will
benefit from this substantial capital infusion but we will benefit
just as much from the support that NEA and our Series A investor, 3i,
can provide."

"The company has developed a micro-ablation device that safely
penetrates and treats multiple layers of tissue non-invasively,"
stated Likens. "Ulthera´s technology is the first to combine high
frequency ultrasound imaging and therapeutic treatment in a single
device. This unique approach enables visualization of target layers of
sub-epidermal tissue immediately before the therapeutic level of
ultrasonic energy is delivered, allowing physicians to see where they
are working below the skin. The epidermal layer of skin is completely
spared, while deeper treatment immediately triggers the body´s natural
healing effect, resulting in a gradual lifting and tightening of skin
tissue in and around the face."

Paul Badawi, a director of 3i, reiterated 3i´s continuing support
of Ulthera and its promising technology platform. "With Ulthera´s
patented ´See and Treat´ approach to cosmetic improvements, patients
can receive optimal energy placement and minimal impact to surrounding
and intervening skin tissue," said Badawi.

The company received a CE Mark (European Conformity approval) for
the Ulthera(TM) System in 2007 and is expecting FDA clearance to sell
products in the U.S. soon. Ulthera will use funds to commercialize its
technology globally, conduct additional product development and
execute more clinical studies to support expanded use of its platform.
Products will be marketed directly to professional dermatologists and
plastic surgeons in the U.S. while the company will rely on a network
of outstanding distributors internationally.

About Ulthera

Ulthera, Inc. develops, sells and markets novel therapeutic
ultrasound-based medical devices into the expanding medical aesthetic
market. This market is defined by elective procedures for consumers
wishing to achieve cosmetic improvement in their appearance. The
company is targeting the non-invasive face lift and skin rejuvenation
market segment, which will exceed $4 B worldwide in 2010. Ulthera was
founded in 2004 and spun-off from Guided Therapy Systems, LLC, a Mesa,
Arizona based ultrasonic medical technologies company.

About NEA

New Enterprise Associates (NEA) is a leading venture capital firm
focused on helping entrepreneurs create and build major new
enterprises that use technology to improve the way we live, work and
play. Since its founding in 1978, the firm has followed the same core
principles: supporting its entrepreneurs, providing an excellent
return to its limited partners, and practicing its profession with the
highest standards and respect. NEA focuses on investments at all
stages of a company´s development, from seed stage through IPO. With
approximately $8.5 billion in committed capital, NEA´s experienced
management team has invested in over 550 companies, of which more than
160 have gone public and more than 230 have been acquired. NEA has
U.S. offices in Chevy Chase, Maryland; Menlo Park, California; and
Baltimore, Maryland. In addition, New Enterprise Associates (India)
Pvt. Ltd. has an office in Bangalore, India and New Enterprise
Associates (Beijing) Ltd. has offices in Beijing and Shanghai, China.
For additional information, visit www.nea.com.

About 3i

Established in 1945, 3i is an international leader in private
equity and venture capital with assets of $16 billion. 3i invests
across Europe, North America and Asia. Our competitive advantage comes
from our international network with more than 250 investment
professionals in 14 countries, unrivaled sector depth and an extensive
portfolio of approximately 750 companies. These underpin the value
that we deliver to our portfolio and to our shareholders.

For more information, visit www.3i.com